News
News
Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India
Latest news
browse:522
time:2021.05.09

BEIJING, May 13, 2021 /PRNewswire/ -- Beijing Time May 10, 2021 — Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) and Shenzhen Pregene Biopharma Co., Ltd. today announced an agreement whereby Dr Reddy's will acquire an exclusive license in the Republic of India for PRG1801, Pregene's single domain antibody-based anti-BCMA chimeric antigen receptor T (CAR-T) cell therapy injection.


Dr. Reddy's acquires the exclusive rights to commercialize PRG1801 in India, and will be responsible for future development including clinical trials, in India. Pregene will be the exclusive supplier of the core material - lentiviral vectors for manufacturing PRG1801. Under the terms of the license agreement, Pregene will receive an upfront payment and future milestone payments of USD 5 million for first indication and up to USD 7.5 million of milestone payments for subsequent indications, and is eligible to receive a double-digit royalty, up to USD 150 million, on future sales of PRG1801 in the licensed territory.  


PRG1801 is an autologous anti-BCMA CAR-T therapy in development for the treatment of relapsed/refractory multiple myeloma, and has already demonstrated strong signs of efficacy and an excellent safety profile in 34 patients in an investigator initiated trial in China. In 2020, PRG1801 was granted NMPA IND clearance, and a Phase I clinical trial of the product candidate is ongoing in China.


This license agreement provides Pregene with a strong, experienced partner in the large Indian market, and expands Dr. Reddy's capacity in the field of immune cell therapy for cancers.


About PRG1801

PRG1801 is an autologous anti-BCMA CAR-T therapy that utilizes a humanized single-domain antibody as the antigen binding domain and lentivirus as a vector. The lentivirus vectors are produced by Pregene using a proprietary serum free suspension production system with gene-therapy-grade quality and a high transduction unit yield. This CAR-T therapy has already demonstrated strong signs of efficacy and


About Pregene

图片5.png


Shenzhen Pregene Biopharma Co. Ltd is a biotechnology company developing innovative cell and gene therapy products based in Shenzhen, China, with laboratory and manufacturing operations in China. Pregene's management and R&D team have prior experience at institutions and companies including the US FDA, Hormel Institute University of Minnesota and the University of Toronto. 


图片6.png


PRG1801, the company's lead program for the treatment of multiple myeloma, has obtained NMPA IND clearance as the Class I new drug, and Phase I clinical trials in China are now ongoing. Pregene's product pipeline includes various cell therapy programs under development for the treatment of hematological malignancies, solid tumors and bone defects.


About Dr. Reddy's

Shenzhen Pregene Biopharma Co. Ltd is a biotechnology company developing innovative cell and gene therapy products based in Shenzhen, China, with laboratory and manufacturing operations in China. Pregene's management and R&D team have prior experience at institutions and companies including the US FDA, Hormel Institute University of Minnesota and the University of Toronto. PRG1801, the company's lead program for the treatment of multiple myeloma, has obtained NMPA IND clearance as the Class I new drug, and Phase I clinical trials in China are now ongoing. Pregene's product pipeline includes various cell therapy programs under development for the treatment of hematological malignancies, solid tumors and bone defects.

About Dr. Reddy's

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com


图片7.png


Investor Relations 

Hongjian LI

CEO


Business Development

Dr. Chaolemeng (Leo) Bao

+86 16675563664

Global Business Development

baoclm@pregene.com

For further information, please contact:

Wonderful Sky Financial Group Ltd.

Joanne Liu

Po@wsfg.hk

Jacky ZHU

jackyZHUJJ@wsfg.hk

SOURCE Shenzhen Pregene Biopharma Co. Ltd